XWELL, Inc. (XWEL) · Oct 20, 2026 · Delisting
Nasdaq deficiency notice — $1.00 minimum bid price; cure deadline April 5, 2027
XWELL’s Nasdaq listing is at risk after a bid-price deficiency notice. The company has until April 5, 2027 to regain compliance.
XWELL is trying to build a pure-play wellness-services business spanning airport and off-airport locations, including XpresSpa, XpresTest and Naples Wax Center, while expanding beyond airports and pursuing international biosecurity opportunities. The filing adds a concrete capital-markets problem to that operating story: Nasdaq has determined that XWELL’s stock traded below the required $1.00 closing bid price for 30 consecutive business days. This is worse than the prior standing assumption because the company now has a formal compliance clock, even though the filing does not mean an immediate delisting.
The immediate business impact is limited, but the remedy could be consequential: XWELL has until April 5, 2027 to record a $1.00-or-higher closing bid price for at least 10 consecutive business days, and it may need to pursue a reverse stock split if the share price does not recover organically. A reverse split would not change the underlying operations, but it could affect the company’s share structure and signals that the listing problem remains unresolved.
This is a warning, not yet a delisting: trading continues on Nasdaq, and the company may qualify for another 180-day compliance period if it meets the additional conditions. However, a closing bid price of $0.10 or less for 10 consecutive trading days would trigger a Staff Delisting Determination, and XWELL acknowledges that it cannot assure a cure.
Bottom line: The filing does not change XWELL’s wellness operations today, but it adds a real listing-risk clock and possible reverse-split overhang to the company’s growth story. Versus the prior situation, that is a meaningful negative development even though delisting is not imminent.
Reverse split decision or bid-price cure by April 5, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!